194 related articles for article (PubMed ID: 10570186)
1. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.
Wang H; Cai Q; Zeng X; Yu D; Agrawal S; Zhang R
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13989-94. PubMed ID: 10570186
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
Wang H; Hang J; Shi Z; Li M; Yu D; Kandimalla ER; Agrawal S; Zhang R
Int J Oncol; 2002 Jul; 21(1):73-80. PubMed ID: 12063552
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.
Nesterova M; Cho-Chung YS
Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):423-33. PubMed ID: 11198926
[TBL] [Abstract][Full Text] [Related]
4. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Cho YS; Cho-Chung YS
Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
[TBL] [Abstract][Full Text] [Related]
5. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
[TBL] [Abstract][Full Text] [Related]
6. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Agrawal S; Kandimalla ER; Yu D; Ball R; Lombardi G; Lucas T; Dexter DL; Hollister BA; Chen SF
Int J Oncol; 2002 Jul; 21(1):65-72. PubMed ID: 12063551
[TBL] [Abstract][Full Text] [Related]
7. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
Nesterova M; Noguchi K; Park YG; Lee YN; Cho-Chung YS
Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.
Tortora G; Caputo R; Damiano V; Bianco R; Pepe S; Bianco AR; Jiang Z; Agrawal S; Ciardiello F
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12586-91. PubMed ID: 9356493
[TBL] [Abstract][Full Text] [Related]
9. Antisense depletion of RIalpha subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells.
Srivastava RK; Srivastava AR; Park YG; Agrawal S; Cho-Chung YS
Breast Cancer Res Treat; 1998 May; 49(2):97-107. PubMed ID: 9696392
[TBL] [Abstract][Full Text] [Related]
10. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
[TBL] [Abstract][Full Text] [Related]
11. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
Tortora G; Bianco R; Damiano V; Fontanini G; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2000 Jun; 6(6):2506-12. PubMed ID: 10873106
[TBL] [Abstract][Full Text] [Related]
12. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention with protein kinase A RIalpha antisense in DMBA-mammary carcinogenesis.
Nesterova MV; Cho-Chung YS
Ann N Y Acad Sci; 2005 Nov; 1058():255-64. PubMed ID: 16394142
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
Tortora G; Caputo R; Damiano V; Fontanini G; Melisi D; Veneziani BM; Zunino F; Bianco AR; Ciardiello F
Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516
[TBL] [Abstract][Full Text] [Related]
17. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
[TBL] [Abstract][Full Text] [Related]
18. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
19. Nuclear translocation of the catalytic subunit of protein kinase A induced by an antisense oligonucleotide directed against the RIalpha regulatory subunit.
Neary CL; Cho-Chung YS
Oncogene; 2001 Nov; 20(55):8019-24. PubMed ID: 11753685
[TBL] [Abstract][Full Text] [Related]
20. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I.
Mani S; Goel S; Nesterova M; Martin RM; Grindel JM; Rothenberg ML; Zhang R; Tortora G; Cho-Chung YS
Ann N Y Acad Sci; 2003 Dec; 1002():252-62. PubMed ID: 14751840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
